192329-80-9

Basic information

• Product Name: 4-(PYRIDIN-4-YLOXY)-BENZENESULFONIC ACID
• Synonyms: 4-(4-PYRIDYLOXY)BENZENESULFONIC ACID;Benzenesulfonic acid, 4-(4-pyridinyloxy)-
• CAS NO: 192329-80-9
• Molecular Formula: C₁₁H₉NO₄S
• Molecular Weight: 251.26
• Mol File: 192329-80-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.427g/cm³
• Refractive Index: 1.613
• CAS DataBase Reference: 4-(PYRIDIN-4-YLOXY)-BENZENESULFONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRIDIN-4-YLOXY)-BENZENESULFONIC ACID(192329-80-9)
• EPA Substance Registry System: 4-(PYRIDIN-4-YLOXY)-BENZENESULFONIC ACID(192329-80-9)

Safety Data

• Hazardous Substances Data: 192329-80-9(Hazardous Substances Data)

Usage

General Description

4-(Pyridin-4-yloxy)-benzenesulfonic acid is a chemical compound with the molecular formula C11H9NO4S. It is commonly used in the pharmaceutical and agricultural industries as a building block for the synthesis of various organic compounds. 4-(PYRIDIN-4-YLOXY)-BENZENESULFONIC ACID is a sulfonic acid derivative, which means it contains a sulfur atom bonded to three oxygen atoms and a hydroxyl group. The pyridin-4-yloxy group is attached to the benzene ring, imparting specific chemical properties and reactivity to the compound. 4-(Pyridin-4-yloxy)-benzenesulfonic acid is utilized in various research and industrial applications due to its functional groups and potential for modification and derivatization to create new compounds with specific properties.

InChI:InChI=1/C11H9NO4S/c13-17(14,15)11-3-1-9(2-4-11)16-10-5-7-12-8-6-10/h1-8H,(H,13,14,15)

Upstream product

• 4783-86-2 4-phenoxypyridine 

Relevant articles and documents

Aromatic sulfone hydroxamic acid metalloprotease inhibitor

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,

Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses

The present invention relates to compounds of formula I:wherein Ar is an aryl group or a heteroaryl group; X is -NH-OH or -OH; R1 is H, -CH(R3)(R4), -C(O)R3, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein R3 is

METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES

Compounds of the formula I: STR1 wherein Y is O or S, Ar is an aryl group or a heteroaryl group, R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or--C(O)R. sub.1, wherein R 1 is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR. sub.2 R 3, wherein R 2 and R 3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, and X is--NH--OH or--OH. Pharmaceutically acceptable prodrugs, salts and solvates of these compounds. Methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. Pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.